A Phase 2 clinical trial involving leuprolide is now recruiting participants, according to a trial update dated September 18, 2026. The study, registered as NCT07650240 and titled "Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial," is evaluating a combination approach involving PSMA-targeted therapy alongside androgen receptor suppression.
The trial is listed with a status of recruiting and is in Phase 2. Leuprolide is an approved compound, and its role in this study relates to androgen receptor suppression as described in the trial title. No outcomes, efficacy data, or safety results have been reported as part of this update.
The trial record does not specify enrollment numbers, eligibility criteria details, or estimated completion dates beyond what is listed above. Additional information about the study design and objectives can be found through the official trial registration.
Readers interested in learning more about leuprolide, including its approved uses and general background, can consult the compound overview for further context.